Cingulate Inc. financial data

Symbol
CING, CINGW on Nasdaq
Industry
Pharmaceutical Preparations
Location
1901 W. 47 Th Place, Kansas City, KS
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 271 % +881%
Debt-to-equity 51.5 %
Return On Equity -241 % -133%
Return On Assets -159 % +63.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.77M shares -24.8%
Common Stock, Shares, Outstanding 3.4M shares +3397%
Entity Public Float 2M USD -74.4%
Common Stock, Value, Issued 340 USD +3300%
Weighted Average Number of Shares Outstanding, Basic 1.77M shares +2045%
Weighted Average Number of Shares Outstanding, Diluted 1.52M shares +1921%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 9.45M USD -39%
General and Administrative Expense 6.2M USD -14.7%
Operating Income (Loss) -15.6M USD +31.3%
Nonoperating Income (Expense) 99.2K USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -15.5M USD +33.9%
Net Income (Loss) Attributable to Parent -15.5M USD +33.9%
Earnings Per Share, Basic -1.83 USD/shares +97.5%
Earnings Per Share, Diluted -10.2 USD/shares +96.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 12.2M USD +23197%
Assets, Current 12.7M USD +2088%
Property, Plant and Equipment, Net 2.1M USD -17.3%
Operating Lease, Right-of-Use Asset 99K USD -73%
Assets 14.9M USD +326%
Accounts Payable, Current 1.27M USD -75.6%
Accrued Liabilities, Current 1.04M USD -37.1%
Liabilities, Current 4.97M USD -51.4%
Operating Lease, Liability, Noncurrent 33.1K USD -91.8%
Liabilities 7.41M USD -28.5%
Retained Earnings (Accumulated Deficit) -108M USD -16.7%
Stockholders' Equity Attributable to Parent 7.46M USD
Liabilities and Equity 14.9M USD +326%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.75M USD -145%
Net Cash Provided by (Used in) Financing Activities 9.89M USD
Net Cash Provided by (Used in) Investing Activities -81.5K USD -119%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 3.4M shares +3397%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.06M USD
Interest Paid, Excluding Capitalized Interest, Operating Activities 308 USD -44.5%
Deferred Tax Assets, Valuation Allowance 17.4M USD +38%
Deferred Tax Assets, Gross 17.8M USD +34.9%
Operating Lease, Liability 131K USD -73.3%
Depreciation 653K USD +12%
Payments to Acquire Property, Plant, and Equipment 81.5K USD +119%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.98M USD -48.6%
Property, Plant and Equipment, Gross 5.4M USD +4.08%
Operating Lease, Liability, Current 131K USD -63.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 9.31M USD +43%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 116M USD +34.7%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 392K USD -30.5%
Interest Expense 634K USD -83.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%